{"transactions":[{"id":4626549,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":13398,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."}],"balance_after":0,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":4626548,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":24258,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."}],"balance_after":0,"derivative":{"exercise_price":9.39,"expiration_date":"2035-05-18","underlying":"Ordinary Shares","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":4626547,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23576,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."}],"balance_after":0,"derivative":{"exercise_price":9.49,"expiration_date":"2034-05-07","underlying":"Ordinary Shares","underlying_shares":23576},"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":4626546,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":22044,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."}],"balance_after":0,"derivative":{"exercise_price":10.95,"expiration_date":"2033-05-01","underlying":"Ordinary Shares","underlying_shares":22044},"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":4626545,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":32666,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a \"Company Option\"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option."}],"balance_after":0,"derivative":{"exercise_price":9.87,"expiration_date":"2033-02-25","underlying":"Ordinary Shares","underlying_shares":32666},"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":4626544,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":6009,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a \"Company RSU Award\") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":4626543,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-09-25T00:31:25.000Z","date":"2026-09-23","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":42137,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the \"Merger Agreement\"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. (\"Parent\"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the \"Merger\"). At the effective time of the Merger (the \"Effective Time\"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer (\"Ordinary Share\") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the \"Per Share Cash Consideration\") and (ii) one contingent value right (a \"CVR\"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time."}],"balance_after":6009,"source":{"system":"sec-edgar","filing":"0001833453-26-000009","document":"form4-09252026_120921.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1833453/000183345326000009/form4-09252026_120921.xml","form_type":"4"}},{"id":731647,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-18T21:39:01.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2027 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2029. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":50000,"derivative":{"exercise_price":9.42,"expiration_date":"2036-06-16","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-276160","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000119312526276160/ownership.xml","form_type":"4"}},{"id":735841,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2026-06-17T01:39:42.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":13398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":13398,"derivative":{"exercise_price":16.64,"expiration_date":"2036-06-11","underlying":"Ordinary Shares","underlying_shares":13398},"source":{"system":"sec-edgar","filing":"0001833453-26-000006","document":"form4-06172026_010638.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000183345326000006/form4-06172026_010638.xml","form_type":"4"}},{"id":735840,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2026-06-17T01:39:42.000Z","date":"2026-06-12","kind":"grant","planned":false,"acquired":true,"shares":6009,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":48146,"source":{"system":"sec-edgar","filing":"0001833453-26-000006","document":"form4-06172026_010638.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000183345326000006/form4-06172026_010638.xml","form_type":"4"}},{"id":759726,"issuer":{"id":4291,"kind":"organization","name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","symbol":"MRVI"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2026-05-28T22:27:16.000Z","date":"2026-05-26","kind":"grant","planned":false,"acquired":true,"shares":46293,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on May 26, 2026, which vest in full upon the earlier of one year from the date of grant or the date of the 2027 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders."}],"balance_after":216200,"source":{"system":"sec-edgar","filing":"0001833453-26-000004","document":"wk-form4_1780007234.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1823239/000183345326000004/wk-form4_1780007234.xml","form_type":"4"}},{"id":797858,"issuer":{"id":4640,"kind":"organization","name":"ANAPTYSBIO, INC","symbol":"ANAB"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2026-04-29T20:05:06.000Z","date":"2026-04-27","kind":"grant","planned":false,"acquired":true,"shares":11250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit (\"RSU\") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/3 of the RSUs shall vest on April 27, 2027 and 1/3 of the RSUs shall vest in equal annual installments until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"1/3 of the RSUs shall vest on April 27, 2027 and 1/3 of the RSUs shall vest in equal annual installments until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date."}],"balance_after":11250,"derivative":{"underlying":"Common Stock","underlying_shares":11250},"source":{"system":"sec-edgar","filing":"0001833453-26-000003","document":"form4-04292026_040401.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1370053/000183345326000003/form4-04292026_040401.xml","form_type":"4"}},{"id":1104580,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-06-20T20:05:18.000Z","date":"2025-06-17","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on June 17, 2026 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on June 17, 2028. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":4.15,"expiration_date":"2035-06-16","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-25-088496","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017025088496/ownership.xml","form_type":"4"}},{"id":1105866,"issuer":{"id":4291,"kind":"organization","name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","symbol":"MRVI"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2025-06-18T22:25:19.000Z","date":"2025-06-16","kind":"grant","planned":false,"acquired":true,"shares":89139,"price":2.16,"value":192540.24,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units awarded under the Maravai LifeSciences Holdings, Inc. 2020 Omnibus Incentive Plan on June 16, 2025, which vest in full upon the earlier of one year from the date of grant or the date of the 2026 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders"}],"balance_after":169907,"source":{"system":"sec-edgar","filing":"0001823239-25-000088","document":"wk-form4_1750285512.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323925000088/wk-form4_1750285512.xml","form_type":"4"}},{"id":1138654,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2025-05-21T23:13:00.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":24258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":24258,"derivative":{"exercise_price":9.39,"expiration_date":"2035-05-18","underlying":"Ordinary Shares","underlying_shares":24258},"source":{"system":"sec-edgar","filing":"0001415889-25-014009","document":"form4-05212025_110557.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588925014009/form4-05212025_110557.xml","form_type":"4"}},{"id":1138653,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2025-05-21T23:13:00.000Z","date":"2025-05-19","kind":"grant","planned":false,"acquired":true,"shares":10649,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":42137,"source":{"system":"sec-edgar","filing":"0001415889-25-014009","document":"form4-05212025_110557.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588925014009/form4-05212025_110557.xml","form_type":"4"}},{"id":1427273,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T19:07:43.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23168,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased by Purchaser for $57.00 per share (the \"Offer Price\"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The Option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":0,"derivative":{"exercise_price":30.52,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":23168},"source":{"system":"sec-edgar","filing":"0001415889-24-021759","document":"form4-08202024_110840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000141588924021759/form4-08202024_110840.xml","form_type":"4"}},{"id":1427272,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T19:07:43.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":12535,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased by Purchaser for $57.00 per share (the \"Offer Price\"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":56.47,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":12535},"source":{"system":"sec-edgar","filing":"0001415889-24-021759","document":"form4-08202024_110840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000141588924021759/form4-08202024_110840.xml","form_type":"4"}},{"id":1427271,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T19:07:43.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":17550,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased by Purchaser for $57.00 per share (the \"Offer Price\"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The Option is fully vested."}],"balance_after":0,"derivative":{"exercise_price":24.49,"expiration_date":"2032-06-08","underlying":"Common Stock","underlying_shares":17550},"source":{"system":"sec-edgar","filing":"0001415889-24-021759","document":"form4-08202024_110840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000141588924021759/form4-08202024_110840.xml","form_type":"4"}},{"id":1427270,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-20T19:07:43.000Z","date":"2024-08-16","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":18111,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On July 7, 2024, Morphic Holding, Inc., a Delaware corporation (the \"Issuer\" or the \"Company\"), entered into an Agreement and Plan of Merger (the \"Merger Agreement\") with Eli Lilly and Company, an Indiana corporation (the \"Parent\"), and Rainier Acquisition Corporation, a Delaware corporation and a wholly owned subsidiary of the Parent (\"Merger Sub\"). Pursuant to the Merger Agreement, the Merger Sub merged with and into the Company (the \"Merger\") with the Company surviving the Merger as a wholly owned subsidiary of the Parent."},{"field":"kind","element":"transactionCoding","label":"F2","text":"(Continued from Footnote 1) Upon the closing (the \"Closing\") of the Merger on August 16, 2024, each share of the Company's Common Stock, par value $0.0001 per share (\"Common Stock\"), was either (x) purchased by Purchaser for $57.00 per share (the \"Offer Price\"), without interest, less any applicable tax withholding or (y) automatically converted into the right to receive the Offer Price in cash without interest, less any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, each Option that was outstanding but not vested as of immediately prior to the Closing (the \"Unvested Option\") became fully vested and exercisable (the \"Vested Option\"). Each Vested Option was automatically cancelled and converted into the right to receive an amount in cash without interest, less any applicable tax withholding, equal to the product obtained by multiplying (i) the excess, if any, of the Offer Price over the exercise price per share of Common Stock underlying such Option by (ii) the number of shares of Common Stock underlying such Option. If the exercise price per share of Common Stock of the underlying Option was equal to or greater than the Offer Price, such Option was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The Company Stock Option (\"Option\") vested as to 25% of the total shares on April 27, 2022, and 9.375% of the remaining shares vests quarterly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":0,"derivative":{"exercise_price":55.46,"expiration_date":"2031-04-26","underlying":"Common Stock","underlying_shares":18111},"source":{"system":"sec-edgar","filing":"0001415889-24-021759","document":"form4-08202024_110840.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000141588924021759/form4-08202024_110840.xml","form_type":"4"}},{"id":1489386,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2024-06-05T19:11:17.000Z","date":"2024-06-04","kind":"grant","planned":false,"acquired":true,"shares":23168,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (a) June 04, 2025 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":23168,"derivative":{"exercise_price":30.52,"expiration_date":"2034-06-03","underlying":"Common Stock","underlying_shares":23168},"source":{"system":"sec-edgar","filing":"0001415889-24-015666","document":"form4-06052024_110614.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000141588924015666/form4-06052024_110614.xml","form_type":"4"}},{"id":1501423,"issuer":{"id":4291,"kind":"organization","name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","symbol":"MRVI"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2024-05-24T21:57:13.000Z","date":"2024-05-23","kind":"grant","planned":false,"acquired":true,"shares":20645,"price":10.78,"value":222553.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted on May 23, 2024, which vest in full upon the earlier of one year from the date of grant or the date of the 2025 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders."}],"balance_after":80768,"source":{"system":"sec-edgar","filing":"0001823239-24-000072","document":"wk-form4_1716587818.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323924000072/wk-form4_1716587818.xml","form_type":"4"}},{"id":1503218,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right To Buy)","published_at":"2024-05-23T23:10:49.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 21, 2025 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 21, 2027. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":25.15,"expiration_date":"2034-05-20","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0000950170-24-064208","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000095017024064208/ownership.xml","form_type":"4"}},{"id":1520371,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2024-05-10T22:06:59.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":23576,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":23576,"derivative":{"exercise_price":9.49,"expiration_date":"2034-05-07","underlying":"Ordinary Shares","underlying_shares":23576},"source":{"system":"sec-edgar","filing":"0001415889-24-012913","document":"form4-05102024_100550.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588924012913/form4-05102024_100550.xml","form_type":"4"}},{"id":1520370,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2024-05-10T22:06:59.000Z","date":"2024-05-08","kind":"grant","planned":false,"acquired":true,"shares":10537,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":31488,"source":{"system":"sec-edgar","filing":"0001415889-24-012913","document":"form4-05102024_100550.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588924012913/form4-05102024_100550.xml","form_type":"4"}},{"id":1826570,"issuer":{"id":4291,"kind":"organization","name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","symbol":"MRVI"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2023-07-19T20:49:17.000Z","date":"2023-07-17","kind":"grant","planned":false,"acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units granted on July 17, 2023, which vest in full upon the earlier of one year from the date of grant or the date of the 2024 Maravai LifeSciences Holdings, Inc. annual meeting of stockholders."}],"balance_after":60123,"source":{"system":"sec-edgar","filing":"0001823239-23-000059","document":"wf-form4_168979974373678.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1823239/000182323923000059/wf-form4_168979974373678.xml","form_type":"4"}},{"id":1869030,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2023-06-02T19:05:26.000Z","date":"2023-06-01","kind":"grant","planned":false,"acquired":true,"shares":12535,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (a) June 1, 2024 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":12535,"derivative":{"exercise_price":56.47,"expiration_date":"2033-05-31","underlying":"Common Stock","underlying_shares":12535},"source":{"system":"sec-edgar","filing":"0001209191-23-034041","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000120919123034041/doc4.xml","form_type":"4"}},{"id":1877642,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2023-05-25T23:33:54.000Z","date":"2023-05-23","kind":"grant","planned":false,"acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2024 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2026. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":17.98,"expiration_date":"2033-05-22","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001610717-23-000069","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000161071723000069/form4.xml","form_type":"4"}},{"id":1904040,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-05-04T22:38:05.000Z","date":"2023-05-02","kind":"grant","planned":false,"acquired":true,"shares":22044,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option may be exercised and shall be vested as to 1/12th of the shares subject to this option when optionee completes each continuous month of service following the grant date and any then remaining unvested shares shall vest on the date of the next annual meeting of the company's shareholders provided the optionee remains in continuous service on such date."}],"balance_after":22044,"derivative":{"exercise_price":10.95,"expiration_date":"2033-05-01","underlying":"Ordinary Shares","underlying_shares":22044},"source":{"system":"sec-edgar","filing":"0001415889-23-007376","document":"form4-05042023_100555.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588923007376/form4-05042023_100555.xml","form_type":"4"}},{"id":1904039,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-05-04T22:38:05.000Z","date":"2023-05-02","kind":"grant","planned":false,"acquired":true,"shares":9132,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":20951,"source":{"system":"sec-edgar","filing":"0001415889-23-007376","document":"form4-05042023_100555.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588923007376/form4-05042023_100555.xml","form_type":"4"}},{"id":1986111,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-03-01T01:17:32.000Z","date":"2023-02-26","kind":"grant","acquired":true,"shares":4666,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"This option shall vest monthly over two months of service from the date of grant and will vest in full upon earlier of the two-month anniversary of Susannah Gray's appointment to the Board or the date of Company's 2023 annual meeting of Shareholders."}],"balance_after":4666,"derivative":{"exercise_price":9.87,"expiration_date":"2033-02-25","underlying":"Ordinary Shares","underlying_shares":4666},"source":{"system":"sec-edgar","filing":"0001415889-23-003569","document":"form4-03012023_010311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588923003569/form4-03012023_010311.xml","form_type":"4"}},{"id":1986110,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Share Option (Right to Buy)","published_at":"2023-03-01T01:17:32.000Z","date":"2023-02-26","kind":"grant","acquired":true,"shares":28000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests monthly over 24 months of service from the date of grant."}],"balance_after":28000,"derivative":{"exercise_price":9.87,"expiration_date":"2033-02-25","underlying":"Ordinary Shares","underlying_shares":28000},"source":{"system":"sec-edgar","filing":"0001415889-23-003569","document":"form4-03012023_010311.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588923003569/form4-03012023_010311.xml","form_type":"4"}},{"id":1986109,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-03-01T01:17:32.000Z","date":"2023-02-26","kind":"grant","acquired":true,"shares":1688,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11819,"source":{"system":"sec-edgar","filing":"0001415889-23-003569","document":"form4-03012023_010311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588923003569/form4-03012023_010311.xml","form_type":"4"}},{"id":1986108,"issuer":{"id":5037,"kind":"organization","name":"Theravance Biopharma, Inc.","symbol":"TBPH"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Ordinary Shares","published_at":"2023-03-01T01:17:32.000Z","date":"2023-02-26","kind":"grant","acquired":true,"shares":10131,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10131,"source":{"system":"sec-edgar","filing":"0001415889-23-003569","document":"form4-03012023_010311.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1583107/000141588923003569/form4-03012023_010311.xml","form_type":"4"}},{"id":2235301,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (Right to Buy)","published_at":"2022-06-10T19:00:45.000Z","date":"2022-06-08","kind":"grant","acquired":true,"shares":17550,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (a) June 8, 2023 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":17550,"derivative":{"exercise_price":24.49,"expiration_date":"2032-06-07","underlying":"Common Stock","underlying_shares":17550},"source":{"system":"sec-edgar","filing":"0001209191-22-036118","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000120919122036118/doc4.xml","form_type":"4"}},{"id":2256405,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2022-05-25T23:01:23.000Z","date":"2022-05-23","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 23, 2023 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 23, 2025. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":7.77,"expiration_date":"2032-05-22","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001567619-22-011719","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761922011719/doc1.xml","form_type":"4"}},{"id":2287527,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2022-04-29T16:14:07.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":18111,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 is being amended to reflect the amount actually granted, as the originally reported share number was in error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option vests as to 25% of the total shares on April 27, 2022, and then 9.375% of the remaining shares shall vest quarterly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":18111,"derivative":{"exercise_price":55.46,"expiration_date":"2031-04-26","underlying":"Common Stock","underlying_shares":18111},"source":{"system":"sec-edgar","filing":"0001209191-22-026235","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000120919122026235/doc4a.xml","form_type":"4/A","original_submission_date":"2021-04-29"}},{"id":2287526,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2022-04-29T16:12:18.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":0,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 is being amended to reflect the amount actually granted, as the originally reported share number was in error."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Not applicable."}],"balance_after":0,"derivative":{"exercise_price":64.79,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":0},"source":{"system":"sec-edgar","filing":"0001209191-22-026234","document":"doc4a.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000120919122026234/doc4a.xml","form_type":"4/A","original_submission_date":"2021-06-17"}},{"id":2314815,"issuer":{"id":15495,"kind":"organization","name":"Apria, Inc.","symbol":"APR"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2022-03-29T16:30:45.000Z","date":"2022-03-29","kind":"disposition_to_issuer","acquired":false,"shares":5059,"price":37.5,"value":189712.5,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Represents a contingent right to receive one share of the Issuer's Common Stock payable in Common Stock, cash or a combination thereof at the discretion of the Issuer's Compensation Committee."},{"field":"kind","element":"transactionCoding","label":"F1","text":"On March 29, 2022, Owens & Minor, Inc. (\"Owens & Minor\") acquired the Issuer pursuant to a certain Agreement and Plan of Merger, dated as of January 7, 2022 (the \"Merger Agreement\"), by and among the Issuer, Owens & Minor and StoneOak Merger Sub Inc., an indirect, wholly owned subsidiary of Owens & Minor (\"Merger Sub\"). In accordance with the Merger Agreement, Merger Sub merged with and into the Issuer (the \"Merger\") with the Issuer surviving the Merger as an indirect, wholly owned subsidiary of Owens & Minor. At the effective time of the Merger, each issued and outstanding share of the Issuer's Common Stock (other than certain excluded shares) automatically converted into the right to receive $37.50 per share in cash (the \"Merger Consideration\"), without interest and subject to applicable withholding tax."},{"field":"kind","element":"transactionCoding","label":"F3","text":"Pursuant to the Merger Agreement, each restricted stock unit (\"RSU\") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Pursuant to the Merger Agreement, each restricted stock unit (\"RSU\") became fully vested and cancelled and entitled the holder to receive an amount of cash, without interest and subject to deduction for any required tax withholding, equal to the number of shares of Common Stock subject to such RSU, immediately prior to the effective time of the Merger, multiplied by the Merger Consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"Represents RSUs granted in 2021, which were originally scheduled to vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":5059},"source":{"system":"sec-edgar","filing":"0000899243-22-012658","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1735803/000089924322012658/doc4.xml","form_type":"4"}},{"id":2496979,"issuer":{"id":4291,"kind":"organization","name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","symbol":"MRVI"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2021-11-23T21:16:06.000Z","date":"2021-11-19","kind":"grant","acquired":true,"shares":4271,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents restricted stock units (\"RSUs\") granted on November 19, 2021, which vest in full one year from the date of the grant."}],"balance_after":36123,"source":{"system":"sec-edgar","filing":"0000899243-21-045773","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1823239/000089924321045773/doc4.xml","form_type":"4"}},{"id":2662753,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Director Stock Option (right to buy)","published_at":"2021-06-17T19:10:01.000Z","date":"2021-06-16","kind":"grant","acquired":true,"shares":12000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option will vest in full on the earlier of (a) June 16, 2022 and (b) the next annual meeting of the issuer's stockholders, subject to the reporting person's provision of service to the issuer on the vesting date."}],"balance_after":12000,"derivative":{"exercise_price":64.79,"expiration_date":"2031-06-16","underlying":"Common Stock","underlying_shares":12000},"source":{"system":"sec-edgar","filing":"0001209191-21-041687","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000120919121041687/doc4.xml","form_type":"4"}},{"id":2669587,"issuer":{"id":15495,"kind":"organization","name":"Apria, Inc.","symbol":"APR"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Units","published_at":"2021-06-14T19:40:22.000Z","date":"2021-06-10","kind":"grant","acquired":true,"shares":5059,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer (\"Common Stock\"). The restricted stock units will be settled in either Common Stock or cash (or a combination thereof) at the discretion of the Issuer's compensation committee."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These restricted stock units vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"These restricted stock units vest on the earlier of (i) June 10, 2022 and (ii) the first regularly scheduled annual meeting of the stockholders of the Company following the grant date."}],"balance_after":5059,"derivative":{"underlying":"Common Stock","underlying_shares":5059},"source":{"system":"sec-edgar","filing":"0000899243-21-023693","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1735803/000089924321023693/doc4.xml","form_type":"4"}},{"id":2704791,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2021-05-20T00:30:57.000Z","date":"2021-05-17","kind":"grant","acquired":true,"shares":22500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Automatically granted pursuant to the terms of the Company's non-employee director compensation program."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 17, 2022 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 17, 2024. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan)."}],"balance_after":22500,"derivative":{"exercise_price":26.89,"expiration_date":"2031-05-16","underlying":"Common Stock","underlying_shares":22500},"source":{"system":"sec-edgar","filing":"0001567619-21-010745","document":"doc1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1650648/000156761921010745/doc1.xml","form_type":"4"}},{"id":2735460,"issuer":{"id":88114,"kind":"organization","name":"Morphic Holding, Inc.","symbol":"MORF"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy Common Stock)","published_at":"2021-04-29T19:10:15.000Z","date":"2021-04-27","kind":"grant","acquired":true,"shares":24000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests as to 25% of the total shares on April 27, 2022, and then 9.375% of the remaining shares shall vest quarterly thereafter, subject to the reporting person's provision of service to the issuer on each vesting date."}],"balance_after":24000,"derivative":{"exercise_price":55.46,"expiration_date":"2031-04-26","underlying":"Common Stock","underlying_shares":24000},"source":{"system":"sec-edgar","filing":"0001209191-21-029109","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1679363/000120919121029109/doc4.xml","form_type":"4"}},{"id":2965641,"issuer":{"id":4291,"kind":"organization","name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","symbol":"MRVI"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2020-11-26T00:58:22.000Z","date":"2020-11-24","kind":"purchase","acquired":true,"shares":20000,"price":27,"value":540000.0,"ownership":{"direct":true},"balance_after":31852,"source":{"system":"sec-edgar","filing":"0000899243-20-032223","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1823239/000089924320032223/doc4.xml","form_type":"4"}},{"id":2969360,"issuer":{"id":4291,"kind":"organization","name":"MARAVAI LIFESCIENCES HOLDINGS, INC.","symbol":"MRVI"},"owners":[{"id":36682,"kind":"person","name":"GRAY SUSANNAH","position":1,"cik":"0001833453","reported_name":"GRAY SUSANNAH","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Class A Common Stock","published_at":"2020-11-23T22:27:40.000Z","date":"2020-11-19","kind":"grant","acquired":true,"shares":11852,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":11852,"source":{"system":"sec-edgar","filing":"0000899243-20-031935","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1823239/000089924320031935/doc4.xml","form_type":"4"}}]}